HEALTH TECHNOLOGY

Happify Health Weaves a New Path as Twill, the Intelligent Healing Company™

Happify Health | July 13, 2022 | Read time : 3 min

Happify Health

Happify Health has announced its transformation to become Twill. This change represents the culmination of a five-year journey to build in-house capabilities, which have enabled the company to transition from wellness apps to a clinical-grade platform that weaves together disparate strands of care to deliver a more connected care experience. As Twill, the company will shorten the distance between need and care to enable delivery of better care at a lower cost for the many, not the few.

Twill offers Sequences™, which are configurable care experiences tailored to meet the needs of customers, specific medical conditions they cover, and the populations they serve. Sequences combine evidence-based digital therapeutics and well-being products, care communities, coaching, and third-party services on a clinical-grade platform designed to work seamlessly with the customer's existing digital solutions and resources. This enables a more precise, personalized and seamless care experience, at scale.

As we’ve grown to deliver care to more communities, the disconnectedness of our industry in addressing mental health along with physical health challenges has become abundantly clear. Instead of contributing to this problem, we saw an opportunity to take a different approach, one where we could make the meaningful connections between technology and humanity, body and mind, and need and care. As we’ve shifted our focus toward weaving together solutions that better support the whole person in the care journey, we wanted a name that better matched our mission: to make healing more intelligent.”

Tomer Ben-Kiki, Chief Executive Officer at Twill

Untangling the complexity of a fragmented healthcare system
Today, there are over 350,000 consumer digital health apps, yet according to McKinsey, 90% of patients are looking for integrated healthcare journeys rather than single-point solutions. At the end of 2021, Twill conducted its own survey of large employers and health plans, to identify the largest barrier to executing a successful digital health strategy. Nearly half of all insurers and over a quarter of employers said that the biggest problem they faced was too many standalone point solutions.

As Twill, the company is untangling the complexity of the healthcare system to deliver care that is more personal and connected. Twill's Intelligent Healing Platform™ integrates with, and augments, the customer’s existing offerings to give more people more choice in their care journey. This open-by-design architecture allows seamless integration with existing digital solutions, enhancing overall personalization and engagement to create a more personal, precise and connected experience. In doing so, Twill aims to usher in a new era of care built on a more human-centered, digital-first approach to guide each person to the care they need, when they need it, in the way they want.

Weaving together a more connected approach to care through Sequences
Sequences™ are the proprietary, configurable solution that enable Twill to provide simpler, more connected support for the care journey of a specific medical condition. Each Sequence is a bespoke configuration of evidence-based digital therapeutics and well-being products, care communities, coaching, third party services, and a customer’s own existing resources. They are open by design, in order to work seamlessly with a customer’s existing digital solutions, enhancing personalization and engagement to create a more personal, precise and connected journey.

By the end of 2022, Twill will offer Sequences for four medical conditions: mental health, MS, pregnancy, and psoriasis. These have been developed with premier partners including Elevance Health Biogen, and Almirall, among others. Twill’s technology and science is designed to be scalable to a broad range of medical conditions.

Intelligently guiding people through a more personalized and precise care journey
Sequences are built on Twill’s Intelligent Healing Platform, which leverages deep understanding of each person’s unique clinical needs and personal preferences to guide people through a hyper-personalized and seamless care experience.

About Twill
Twill is The Intelligent Healing Company™, shortening the distance between need and care by intelligently guiding each person to the care they need, when they need it, in the way they want. The company delivers Sequences™, fully configurable, scientifically designed, digital-first solutions that support the care journey for specific medical conditions. Twill does this for pharmaceutical companies, health plans, jumbo employers, and those they serve. Available across 10 languages and covering more than 18 million lives, Twill creates a more precise, personal, engaging, and effective experience at scale for the many, not the few. 

Spotlight

15 Top Health Systems 2015.


Other News
HEALTH TECHNOLOGY

BulletinHealthcare Launches Family Medicine Today in Partnership with American Academy of Family Physicians

BulletinHealthcare | August 16, 2022

BulletinHealthcare, a leading provider of news briefings for top U.S. medical associations, announced that it has launched its latest briefing for members of the American Academy of Family Physicians Family Medicine Today. Family Medicine Today is distributed via email to AAFP members by 9:00 a.m. ET every weekday morning. The publication provides family medicine physicians with relevant medical, practice management, and health policy news, delivered directly to their inbox in a concise, user-friendly format. The content of the briefings follows BulletinHealthcare's signature curation and distillation of the day's most important news stories, selected from thousands of sources by its team of healthcare analysts. "We are pleased to partner with the American Academy of Family Physicians to produce an exciting publication to serve their members. Our analyst group is unmatched in their expertise in producing handcrafted news briefings for busy healthcare professionals. And, with this new partnership, BulletinHealthcare adds a valuable new audience to the nearly one million healthcare professionals we reach each day." Danielle Sturgis, Vice President of Partnerships at BulletinHealthcare "The typical family physician sees more than 80 patients a week. As advocates for family physicians and their patients, the AAFP works to deliver high-value resources that give our members more time and energy for their patients," said Shawn Martin, Executive Vice President and Chief Executive Officer of the American Academy of Family Physicians. "In Family Medicine Today, BulletinHealthcare will curate content specifically for family physicians, providing a quick and convenient way for our members to stay current on news and trends that affect family medicine." Advertising opportunities in AAFP's Family Medicine Today are now available, including special founding advertiser packages for 2022. About BulletinHealthcare BulletinHealthcare, a Cision® Insights solution, is a healthcare provider-focused digital publisher that – through partnerships with more than 30 leading medical associations and the Cleveland Clinic – curates and disseminates the stories and research that matter most to verified physicians, dentists, nurses, and other HCPs. BulletinHealthcare delivers nearly one million briefings every weekday to our partners' members and stakeholders. About the American Academy of Family Physicians Founded in 1947, the AAFP represents 127,600 physicians and medical students nationwide. It is the largest medical society devoted solely to primary care. Family physicians conduct approximately one in five office visits -- that's 192 million visits annually or 48 percent more than the next most visited medical specialty. Today, family physicians provide more care for America's underserved and rural populations than any other medical specialty. Family medicine's cornerstone is an ongoing, personal patient-physician relationship focused on integrated care.

Read More

HEALTH TECHNOLOGY

Software Identifies Unreported Mental Health Issues in Teens

Advanced Metrics | August 26, 2022

Advanced Metrics and Samaritan Counseling Center today announced the release of QUALO Behavioral Health, a cloud-based software designed to proactively screen teens for mental and emotional wellbeing. "An easy to implement mental health screening strategy gives schools a targeted opportunity to engage and empower students who need connected to community resources because they are struggling with feelings of depression, anxiety, and suicidal thoughts." Steve Schedler, Samaritan Counseling QUALO Behavioral Health software revolutionizes teen mental health screening by innovatively simplifying the entire screening process. The software guides youth through industry standard screening tools to understand their current emotional wellbeing. Mental health professionals are immediately provided with data supporting an "at-risk" or "not at risk" identification and are guided through an intentional follow-up process. "With the mental health crisis facing teens today, we knew it was critical to develop a software that supports teen's mental well-being and normalizes conversations about mental health. We designed this software so schools can implement it independently or through collaboration with an outside agency. Either way, the platform will support students, inform administrators, and enhance any mental health strategy a school is implementing." Steven Herr PhD, Advanced Metrics Advanced Metrics is a Software as a Service company dedicated to improving the health of individuals and communities through science informed software and human centered data analysis. Advanced Metrics designed QUALO, a comprehensive web-based solution, to empower human service organizations to deliver services that generate quality life outcomes. TeenHope is a student mental and emotional wellbeing education and screening program in Lancaster, PA. TeenHope is supported by Samaritan Counseling Center, which provides professional counseling, consultation and education for individuals, couples, businesses, and clergy.

Read More

HEALTH TECHNOLOGY

Johnson & Johnson Opens State-of-the-Art Science and Technology Campus in San Francisco Bay Area

Johnson & Johnson | September 21, 2022

Johnson & Johnson opened its San Francisco Bay Campus, a state-of-the-art Research & Development facility in the Bay Area, one of the world’s most established global hubs for innovation and entrepreneurship. The nearly 200,000 square-foot facility will house up to 400 employees, more than doubling the R&D presence of Johnson & Johnson in the Bay Area. The campus bridges key scientific and technological capabilities by co-locating Janssen R&D, Johnson & Johnson Innovation and Johnson & Johnson Technology. It will further integrate the Company into the Bay Area innovation ecosystem to strengthen and increase collaborations with innovators to accelerate growth. “Johnson & Johnson’s expanded presence in the Bay Area affirms our commitment to combining science and technology to deliver transformative healthcare solutions. On this campus, our talented teams will use their diverse experience and expertise to tackle society’s greatest health challenges to create a better future for patients.” Joaquin Duato, Chief Executive Officer, Johnson & Johnson The R&D focus at the new site spans Janssen’s therapeutic areas and key functions, including emerging science and technologies for gene and RNA therapies, novel treatments and approaches for retinal and infectious diseases, and advanced data science, including artificial intelligence and machine learning. Co-locating expertise at the site will enable the expansion of the Company’s world-class discovery engine and industry-leading pipeline. “Our new state-of-the-art science facility in the Bay Area will further strengthen our R&D capabilities and transform how we discover, develop and deliver innovative medicines faster and more efficiently. By integrating drug discovery, data science and digital health, we aim to accelerate the growth of our best-in-class portfolio and deliver better health outcomes for people worldwide,” said James Merson, Ph.D., Site Head, San Francisco Bay Campus and Global Therapeutic Area Head, Infectious Diseases, Janssen Research & Development, LLC. The Johnson & Johnson Innovation Center in California has facilitated investments and collaborations to accelerate early-stage healthcare innovation with academic and industry partners in the Bay Area and greater California ecosystem since 2014. The San Francisco Bay Campus, along with the Company’s JLABS @ South San Francisco, will continue to enable the Company to build strong relationships with entrepreneurs, scientists and investors to support and invest in highly differentiated innovations that extend and improve lives everywhere. Additionally, given the convergence of healthcare and technology in the region, the Company will increase its focus on the Johnson & Johnson Technology organization to enhance its ability to create innovative digital solutions to advance human health. Building on Johnson & Johnson’s long-standing commitment to use its expertise and resources to reduce the environmental footprint of its operations, the Bay Area hub is designed as a high-performance green campus, reinforcing the Company’s pledge to be responsible stewards in creating a healthy, more sustainable future. The aim is for the new site to receive Silver Leadership in Energy & Environmental Design (LEED) certification, the most widely used green building rating system in the world. About Johnson & Johnson At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at @JanssenGlobal. Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson. About Johnson & Johnson Innovation Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists, and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. About Johnson & Johnson Technology Johnson & Johnson Technology solves big problems in healthcare through technology and digital innovation. Just as doctors use scalpels, we use data science, algorithms, artificial intelligence, robotics, and other digital solutions to transform patients’ lives. From guiding patients through treatment to accelerating vaccine development to enabling employees to work seamlessly from any location, our digital tools infuse our products with novelty, dexterity, and ease.

Read More

HEALTH TECHNOLOGY

Prospection partners with leading Japanese healthcare data provider Medical Data Vision to improve treatment access for patients

Prospection | September 06, 2022

Health analytics pioneer, Prospection has announced a unique global data access agreement with leading Japanese medical data company Medical Data Vision Co., Ltd. to accelerate healthcare analytics globally. The agreement, covering the world's second largest pharmaceutical market, will provide global pharmaceutical companies and researchers access to comprehensive and longitudinal data covering more than 40 million people in Japan at more than 470 hospitals. Combining predictive analytics and machine learning with real-world healthcare data, Prospection's agreement with MDV will provide pharmaceutical companies across the world with unique access to patient diagnostic and medication data from hospitals across Japan, unlocking potential to assess an unlimited number of treatment programs in the region. The agreement also enables access to patient history and prefecture level data, allowing analysis of disease progression, disease outcomes and the mapping of disease courses to provide evidence on areas where development can address unmet needs. When distilled further, this creates an opportunity to assess patient data on a regional level to find geographical areas where patients or health centres require additional support for specific disease and conditions. Prospection's access to Japan's most comprehensive medical data sets is a significant milestone for the company. Prospection currently provides real-time access to longitudinal patient data across 15 regions globally including Australia, New Zealand, Japan, South Korea, Taiwan, USA and the UK. The company's latest announcement with Medical Data Vision will build on this work, providing Prospection with access to one of Japan's largest healthcare databases. "We are delighted to announce our latest agreement with Medical Data Vision. This partnership demonstrates a shared commitment to improving patient outcomes and marks a significant milestone in Prospection's mission to deliver real community benefits to patients across the globe. "As one of the largest pharmaceutical markets in the world, Japan has incredibly rich datasets. Working with Medical Data Vision gives us the opportunity to access a dataset of approximately 40 million patients, creating a unique opportunity to use advanced analytic tools to accelerate precision medicine to enable the right patient to receive the right treatment at the right time in their journey. "The outcomes of this partnership will play a key role in understanding the full cycle of patient health conditions and disease journeys in areas including immuno-oncology, immune disorders, cardiovascular and metabolic conditions allowing researchers and pharmaceutical companies globally to better understand the different patient characteristics, treatments and respective outcomes." Eric Chung, CEO and Co-founder, Prospection "We are very excited to be working with MDV in our latest data access agreement. Combining MDV's large and comprehensive dataset with Prospections global reach and extensive expertise working with datasets across the world will not only allow MNC pharmaceutical companies to work with patient data from Japan, but will also open a broader understanding of different health conditions across the world. This agreement brings us one step closer to enhancing precision medicine to find the 40% of patients that can be optimised." About Prospection Prospection is a pioneer in health data analytics technology. We are on a mission to make advancements to precision medicine through real world evidence, with an aim to put the right patient on the right treatment at the right time. Applying advanced ML algorithms to real-world data we unearth health journey and treatment insights by analysing longitudinal data for hundreds of millions of patients to see how drug treatments are used after the clinical trial. Delivering actionable real-world evidence that enables better outcomes for patients, across the world. Prospection is guided by credentialled experts and innovative leaders within their respective fields. Globally, we work with over 15 large health data sets applying our expertise to examine health patterns. Working with government and researchers through to our core client base in the pharma/biopharmaceutical industry, we have delivered insights across more than 90 therapeutic indications. Including rare and complex diseases such as oncology, immuno-oncology, virology, metabolic conditions, respiratory and cardiovascular disease. Prospection is backed by investors including Ellerston, Horizons Ventures and Main Sequence, and commercially with CRO Novotech. About Medical Data Vision (MDV) MDV is an accumulation of anonymously processed data with secondary usage permission from medical institutions. The actual number of patients in the "hospital data" centered on the acute phase is 40.42 million. In addition, by holding data from the health insurance association, data on the recovery period and chronic period has been enhanced, and in addition to information by hospital/clinic, it has become possible to track information on transfer destinations. "Health insurance data" was 7.84 million people (same).

Read More